Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis

  Free Subscription


Articles published in J Med Virol

Retrieve available abstracts of 133 articles:
HTML format
Text format



Single Articles


    September 2018
  1. PENG H, Zhang L, Feng Y, Tang H, et al
    A cross-sectional serum investigation of a clustering HCV infection in Southwest China.
    J Med Virol. 2018 Sep 11. doi: 10.1002/jmv.25315.
    PubMed     Text format     Abstract available


  2. KHOSRAVI A, Karimi-Sari H, Abedi-Andani M, Behnava B, et al
    Acute Changes in Cardiac Function by Direct-acting Antiviral Therapy for Hepatitis C Infected Thalassemia Patients.
    J Med Virol. 2018 Sep 11. doi: 10.1002/jmv.25314.
    PubMed     Text format     Abstract available


  3. GUOPING D, Xiaoshan L, Musa TH, Yu J, et al
    The Nationwide Distribution and Trends of Hepatitis C Virus Genotypes in Mainland China.
    J Med Virol. 2018 Sep 7. doi: 10.1002/jmv.25311.
    PubMed     Text format     Abstract available


  4. SASAKI R, Meyer K, Moriyama M, Kato N, et al
    Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
    J Med Virol. 2018 Sep 7. doi: 10.1002/jmv.25310.
    PubMed     Text format     Abstract available


  5. LI Y, Zeng Y, Zeng G, Li J, et al
    The Effects of Direct-Acting Antiviral Agents on the Frequency of Myeloid-Derived Suppressor Cells and Natural Killer Cells in Patients with Chronic Hepatitis C.
    J Med Virol. 2018 Sep 1. doi: 10.1002/jmv.25302.
    PubMed     Text format     Abstract available


    August 2018
  6. CANGIN C, Focht B, Harris R, Strunk JA, et al
    Hepatitis E Seroprevalence in the United States: Results for Immunoglobulins IgG and IgM.
    J Med Virol. 2018 Aug 31. doi: 10.1002/jmv.25299.
    PubMed     Text format     Abstract available


  7. TANG X, Yan L, Li H, Du L, et al
    Increased Expression of Phosphoenolpyruvate Carboxykinase Cytoplasmic Isoform by Hepatitis B Virus X Protein Affects HBV Replication.
    J Med Virol. 2018 Aug 31. doi: 10.1002/jmv.25300.
    PubMed     Text format     Abstract available


  8. GOURARI S, Brichler S, Le Gal F, Abdou-Chekaraou SM, et al
    Hepatitis B Virus and Hepatitis Delta Virus (HDV) Subtypes Circulating in Algeria and Seroprevalence of HDV Infection.
    J Med Virol. 2018 Aug 31. doi: 10.1002/jmv.25301.
    PubMed     Text format     Abstract available


  9. CELLA E, Golgochvea-Markova E, Sagnelli C, Scolamacchia V, et al
    Human hepatitis E virus circulation in Bulgaria: deep Bayesian phylogenetic analysis for viral spread control in the country.
    J Med Virol. 2018 Aug 31. doi: 10.1002/jmv.25296.
    PubMed     Text format     Abstract available


  10. ELBAZ T, Abdo M, Omar H, Hassan EA, et al
    Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
    J Med Virol. 2018 Aug 23. doi: 10.1002/jmv.25287.
    PubMed     Text format     Abstract available


  11. JORDIER F, Deligny ML, Barre R, Robert C, et al
    Human pegivirus (HPgV) isolates characterized by deep sequencing from HCV- and HIV-RNA positive blood donations, France.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25290.
    PubMed     Text format     Abstract available


  12. CASTRO VOL, Tejada-Strop A, Weis SMS, Stabile AC, et al
    Evidence of hepatitis E virus infections among persons who use crack cocaine from the Midwest region of Brazil.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25288.
    PubMed     Text format     Abstract available


  13. EL-HEFNY MA, Fouad SA, Hussein TD, Abdel-Hameed R, et al
    Circulating miRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25294.
    PubMed     Text format     Abstract available


  14. JIN J, Xu H, Wu R, Niu J, et al
    Aberrant DNA methylation profile of hepatitis B virus infection.
    J Med Virol. 2018 Aug 17. doi: 10.1002/jmv.25284.
    PubMed     Text format     Abstract available


  15. AKUTA N, Sezaki H, Suzuki F, Fujiyama S, et al
    Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25278.
    PubMed     Text format     Abstract available


  16. KAHYESH-ESFANDIARY R, Sadigh ZA, Esghaei M, Bastani MN, et al
    Detection of HCV Genome in Peripheral Blood Mononuclear Cells of Iranian Seropositive and HCV RNA negative in Plasma of Patients with Beta-thalassemia Major: Occult HCV Infection.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25279.
    PubMed     Text format     Abstract available


  17. LU T, Han Y, Zhang R, Zhang K, et al
    Quantitative detection of hepatitis C virus RNA in urine of patients with chronic hepatitis C using a novel real-time PCR assay.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25280.
    PubMed     Text format     Abstract available


  18. FLORES GL, Cruz HM, Miguel JC, Potsch DV, et al
    Assessing Hepatitis B immunity using dried blood spot samples from HIV(+) individuals.
    J Med Virol. 2018 Aug 7. doi: 10.1002/jmv.25275.
    PubMed     Text format     Abstract available


  19. PRAKASH S, Shukla S, Ramakrishna V, Jain A, et al
    Distribution of Hepatitis C Genotypes in Uttar Pradesh, India; Rare Genotype 4 Detected.
    J Med Virol. 2018 Aug 7. doi: 10.1002/jmv.25277.
    PubMed     Text format     Abstract available


  20. YANG D, Hu T, Wu X, Li K, et al
    Droplet digital polymerase chain reaction for detection of clinical hepatitis B virus DNA samples.
    J Med Virol. 2018 Aug 7. doi: 10.1002/jmv.25276.
    PubMed     Text format     Abstract available


    July 2018
  21. HARDTKE S, Rocco R, Ogata J, Braga S, et al
    Risk factors and seroprevalence of Hepatitis E evaluated in frozen serum samples (2002-2003) of pregnant women compared to female blood donors in a Southern Region of Brazil.
    J Med Virol. 2018 Jul 31. doi: 10.1002/jmv.25274.
    PubMed     Text format     Abstract available


  22. CHIHAB H, Jadid FZ, Foka P, Zaidane I, et al
    PD-1 3'untranslated region polymorphism is associated with spontaneous clearance of Hepatitis B virus infection.
    J Med Virol. 2018 Jul 17. doi: 10.1002/jmv.25265.
    PubMed     Text format     Abstract available


  23. MORIO K, Imamura M, Kawakami Y, Nakamura Y, et al
    Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
    J Med Virol. 2018 Jul 17. doi: 10.1002/jmv.25267.
    PubMed     Text format     Abstract available


  24. HASHEM M, Zaghla H, Zakaria Z, Allam WR, et al
    High spontaneous clearance of symptomatic iatrogenic acute hepatitis C genotype 4 infection.
    J Med Virol. 2018 Jul 16. doi: 10.1002/jmv.25270.
    PubMed     Text format     Abstract available


  25. YAMASAKI K, Tanaka J, Kurisu A, Akita T, et al
    Natural course of persistent hepatitis B virus infection in HBe antigen-positive and -negative cohorts in Japan based on the Markov model.
    J Med Virol. 2018 Jul 11. doi: 10.1002/jmv.25260.
    PubMed     Text format     Abstract available


  26. ZHAO N, Zheng W, Wu D, Wang X, et al
    Clinical value of HCcAg levels in monitoring acute hepatitis C spontaneous clearance or treatment-induced clearance.
    J Med Virol. 2018 Jul 11. doi: 10.1002/jmv.25256.
    PubMed     Text format     Abstract available


  27. JOGEDA EL, Avi R, Pauskar M, Kallas E, et al
    Association of IFNlambda4 rs12979860 Polymorphism with the Acquisition of HCV and HIV Infections among People Who Inject Drugs.
    J Med Virol. 2018 Jul 10. doi: 10.1002/jmv.25258.
    PubMed     Text format     Abstract available


  28. EL BATAE H, Amer I, Kobtan A, Saied SM, et al
    Seroprevalence of hepatitis C virus among the newcomer students, Kafrelsheikh University, Egypt.
    J Med Virol. 2018 Jul 7. doi: 10.1002/jmv.25249.
    PubMed     Text format     Abstract available


    June 2018
  29. DEGEFA B, Gebreeyesus T, Gebremedhin Z, Melkamu G, et al
    Prevalence of hepatitis B virus, hepatitis C virus and human immunodeficiency virus among blood donors of Mekelle blood bank, Northern Ethiopia: A three year retrospective study.
    J Med Virol. 2018 Jun 15. doi: 10.1002/jmv.25248.
    PubMed     Text format     Abstract available


  30. ZHANG W, Huang J, Wang M, Song D, et al
    Characterization of monocytic and granulocytic subsets of myeloid-derived suppressor cells in blood donors with occult hepatitis B virus infection.
    J Med Virol. 2018 Jun 13. doi: 10.1002/jmv.25242.
    PubMed     Text format     Abstract available


  31. KIM HY, Yoo JJ, Oh S, Yu SJ, et al
    Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study.
    J Med Virol. 2018 Jun 13. doi: 10.1002/jmv.25241.
    PubMed     Text format     Abstract available


  32. WAKED I, Esmat G, Fouad R, Allam N, et al
    Change in hepatic profile in hepatitis C virus genotype 4 patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: a subanalysis of the AGATE-II study.
    J Med Virol. 2018 Jun 13. doi: 10.1002/jmv.25243.
    PubMed     Text format     Abstract available


    May 2018
  33. CREMER J, Hofstraat SHI, van Heiningen F, Veldhuijzen IK, et al
    Genetic variation of Hepatitis B surface antigen among acute and chronic hepatitis B virus infections in the Netherlands.
    J Med Virol. 2018 May 24. doi: 10.1002/jmv.25232.
    PubMed     Text format     Abstract available


  34. LARSSON SB, Tripodi G, Raimondo G, Saitta C, et al
    Integration of hepatitis B virus DNA in chronically infected patients assessed by Alu-PCR.
    J Med Virol. 2018 May 24. doi: 10.1002/jmv.25227.
    PubMed     Text format     Abstract available


  35. MARYAM M, Idrees M
    Study of promoter hypomethylation profiles of RAS oncogenes in Hepatocellular Carcinoma derived from Hepatitis C virus genotype 3a in Pakistani population.
    J Med Virol. 2018 May 9. doi: 10.1002/jmv.25221.
    PubMed     Text format     Abstract available


  36. CELLA E, Riva E, Angeletti S, Fogolari M, et al
    Genotype I Hepatitis A virus introduction in Italy: Bayesian phylogenetic analysis to date different epidemics.
    J Med Virol. 2018 May 8. doi: 10.1002/jmv.25220.
    PubMed     Text format     Abstract available


  37. CAO D, Ni YY, Walker M, Huang YW, et al
    Roles of the genomic sequence surrounding the stem-loop structure in the junction region including the 3' terminus of ORF1 in hepatitis E virus replication.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25215.
    PubMed     Text format     Abstract available


  38. ALEM SA, Said M, Anwar I, Abdellatif Z, et al
    Improvement of LSM, ARFI measurements and non-invasive fibrosis markers after DAAs for HCV G4 recurrence post living donor liver transplantation: Egyptian cohort.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25210.
    PubMed     Text format     Abstract available


  39. DE DIEU LONGO J, Bouassa RM, Simaleko MM, Kouabosso A, et al
    Usefulness of simultaneous screening for HIV- and HCV- specific antibodies and HBsAg by capillary-based multiplex rapid diagnostic test to strengthen linkage-to-care in sub-Saharan patients attending sexually transmitted infections clinic.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25209.
    PubMed     Text format     Abstract available


    April 2018
  40. MOSITES E, Gounder P, Snowball M, Morris J, et al
    Hepatitis A vaccine immune response 22 years after vaccination.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25197.
    PubMed     Text format     Abstract available


  41. LAGO BV, Mello FCA, Barros TM, Mello VM, et al
    Hepatitis D infection in Brazil: prevalence and geographical distribution of anti-Delta antibody.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25196.
    PubMed     Text format     Abstract available


  42. NIGUSE S, Hailekiros H, Buruh G, Dejene T, et al
    Seroprevalence and risk factors of Hepatitis E Virus infection among pregnant women attending antenatal care in health facilities of Tigray, Northern Ethiopia.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25190.
    PubMed     Text format     Abstract available


  43. LIU K, Xie M, Lu X, Yu H, et al
    Mutations Within the Major Hydrophilic Region(MHR) of Hepatitis B Virus from individuals with simultaneous HBsAg and anti-HBs in Guangzhou, southern China.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25188.
    PubMed     Text format     Abstract available


  44. Z M, H K, E M, N B, et al
    Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About 8 cases resolved by a sequencing method.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25191.
    PubMed     Text format     Abstract available


  45. LAGO BV, Mello FCA, Barros TM, Mello VM, et al
    Hepatitis D infection in Brazil: prevalence and geographical distribution of anti-Delta antibody.
    J Med Virol. 2018 Apr 14. doi: 10.1002/jmv.25088.
    PubMed     Text format     Abstract available


  46. MOSITES E, Gounder P, Snowball M, Morris J, et al
    Hepatitis A vaccine immune response 22 years after vaccination.
    J Med Virol. 2018 Apr 12. doi: 10.1002/jmv.25089.
    PubMed     Text format     Abstract available


  47. VISCO-COMANDINI U, Lapa D, Lionetti R, Taibi C, et al
    Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols.
    J Med Virol. 2018 Apr 3. doi: 10.1002/jmv.25084.
    PubMed     Text format     Abstract available


  48. YANG R, Gao N, Chang Q, Meng X, et al
    The role of IDO, IL-10 and TGF-beta in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.
    J Med Virol. 2018 Apr 3. doi: 10.1002/jmv.25083.
    PubMed     Text format     Abstract available


    March 2018
  49. YANG N, Feng J, Zhou T, Li Z, et al
    Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients.
    J Med Virol. 2018 Mar 30. doi: 10.1002/jmv.25080.
    PubMed     Text format     Abstract available


  50. DENG H, Deng X, Liu Y, Xu Y, et al
    Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or co-infected with HBV or HCV in China.
    J Med Virol. 2018 Mar 24. doi: 10.1002/jmv.25078.
    PubMed     Text format     Abstract available


  51. ANTONIO UL, Alicia OM, Antonio MJ, Elena GM, et al
    Presence of rare hepatitis C virus subtypes, 2j, 2k and 2r, in Mexico City as identified by sequencing.
    J Med Virol. 2018 Mar 6. doi: 10.1002/jmv.25070.
    PubMed     Text format     Abstract available


    February 2018
  52. COLOMBATTO P, Barbera C, Bortolotti F, Maina AM, et al
    HBV Pre-Core mutant in genotype-D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood.
    J Med Virol. 2018 Feb 28. doi: 10.1002/jmv.25068.
    PubMed     Text format     Abstract available


  53. CORDIE A, Salama A, El-Sharkawy M, El-Nahaas SM, et al
    Comparing the efficiency of Fib-4, Egy-score, APRI and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C.
    J Med Virol. 2018 Feb 24. doi: 10.1002/jmv.25064.
    PubMed     Text format     Abstract available


  54. SHOUSHA HI, Abdelaziz RA, Azab SM, Khairy M, et al
    Effect of Treatment with Direct Acting Antivirals on Body Mass Index and Hepatic Steatosis in Chronic Hepatitis C.
    J Med Virol. 2018 Feb 22. doi: 10.1002/jmv.25062.
    PubMed     Text format     Abstract available


  55. ZHOU S, Ren L, Xia X, Miao Z, et al
    Hepatitis E virus infection in HIV-infected patients: a large cohort study in Yunnan province, China.
    J Med Virol. 2018 Feb 19. doi: 10.1002/jmv.25060.
    PubMed     Text format     Abstract available


  56. RAN M, Huang J, Liang H, Jiang J, et al
    Alcohol attenuates anti-HCV function of IFN-lambda1 through up-regulation of PLASy expression in human hepatic cells.
    J Med Virol. 2018 Feb 15. doi: 10.1002/jmv.25053.
    PubMed     Text format     Abstract available


  57. DE CASTRO SANT' ANNA C, de Almeida MKC, Ferreira P, de Oliveira RG, et al
    PREVALENCE OF OCCULT HEPATITIS B IN A POPULATION FROM THE BRAZILIAN AMAZON REGION.
    J Med Virol. 2018 Feb 15. doi: 10.1002/jmv.25051.
    PubMed     Text format     Abstract available


  58. MANCINELLI S, Pirillo MF, Liotta G, Andreotti M, et al
    ANTIBODY RESPONSE TO HEPATITIS B VACCINE IN HIV-EXPOSED INFANTS IN MALAWI AND CORRELATION WITH HBV INFECTION ACQUISITION.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25049.
    PubMed     Text format     Abstract available


  59. OGATA F, Akuta N, Kobayashi M, Fujiyama S, et al
    Amino Acid Substitutions in the Hepatitis C Virus Core Region Predict Hepatocarcinogenesis Following Eradication of HCV RNA by All-Oral Direct-Acting Antiviral Regimens.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25047.
    PubMed     Text format     Abstract available


  60. GRANDAL M, Pernas B, Tabernilla A, Marino A, et al
    Prevalence of NS5A Resistance Associated Substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on Current Therapeutic Strategies.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25048.
    PubMed     Text format     Abstract available


  61. ANASTASIOU OE, Widera M, Korth J, Kefalakes H, et al
    Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA.
    J Med Virol. 2018;90:282-290.
    PubMed     Text format     Abstract available


    January 2018
  62. BOGLIONE L, Cariti G, Ghisetti V, Burdino E, et al
    Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: a retrospective analysis.
    J Med Virol. 2018 Jan 31. doi: 10.1002/jmv.25038.
    PubMed     Text format     Abstract available


  63. SUN LJ, Yu JW, Shi YG, Zhang XY, et al
    Hepatitis C virus core protein induces dysfunction of liver sinusoidal endothelial cell by down-regulation of silent information regulator 1.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25034.
    PubMed     Text format     Abstract available


  64. MOUREZ T, Decroos A, Goria O, Montialoux H, et al
    Misidentification of recombinant hepatitis C virus leading to treatment failure with direct acting antivirals.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25035.
    PubMed     Text format     Abstract available


  65. MARCIANO S, Haddad L, Reggiardo MV, Peralta M, et al
    Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: a real world study.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25033.
    PubMed     Text format     Abstract available


  66. ALIDJINOU EK, Michel C, Canva V, Ajana F, et al
    Very slow decline of hepatitis B virus surface antigen and core related antigen in chronic hepatitis B patients successfully treated with nucleos(t)ide analogues.
    J Med Virol. 2018 Jan 9. doi: 10.1002/jmv.25028.
    PubMed     Text format     Abstract available


  67. MARIO S, Carmine M, Stefania P, Margherita M, et al
    VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS.
    J Med Virol. 2018 Jan 9. doi: 10.1002/jmv.25022.
    PubMed     Text format     Abstract available


  68. GAMIL M, Alboraie M, El-Sayed M, Elsharkawy A, et al
    Novel scores combining AFP with non-invasive markers for prediction of liver fibrosis in chronic hepatitis C patients.
    J Med Virol. 2018 Jan 6. doi: 10.1002/jmv.25026.
    PubMed     Text format     Abstract available


  69. OHYA K, Akuta N, Suzuki F, Fujiyama S, et al
    Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
    J Med Virol. 2018 Jan 5. doi: 10.1002/jmv.25023.
    PubMed     Text format     Abstract available


    December 2017
  70. ZHU MY, Chen PZ, Li J, Yu DM, et al
    Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-alpha treatment in HBeAg-positive chronic hepatitis B patients.
    J Med Virol. 2017 Dec 16. doi: 10.1002/jmv.25010.
    PubMed     Text format     Abstract available


  71. MATHUR P, Emmanuel B, Sneller M, Zhang X, et al
    Recovery of Hepatitis C Specific T-cell Responses after Rituximab Therapy in Hepatitis C Mixed Cryoglobulinemic Vasculitis.
    J Med Virol. 2017 Dec 13. doi: 10.1002/jmv.25002.
    PubMed     Text format     Abstract available


    November 2017
  72. ISHIGAMI M, Hayashi K, Honda T, Kuzuya T, et al
    Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
    J Med Virol. 2017 Nov 7. doi: 10.1002/jmv.24978.
    PubMed     Text format     Abstract available


  73. SU S, Fairley CK, Sasadeusz J, He J, et al
    HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    J Med Virol. 2017 Nov 1. doi: 10.1002/jmv.24988.
    PubMed     Text format     Abstract available


    October 2017
  74. KIM DY, Lee HW, Song JE, Kim BK, et al
    Switching from Tenofovir and Nucleoside Analogue Therapy to Tenofovir Monotherapy in Virologically Suppressed Chronic Hepatitis B Patients with Antiviral Resistance.
    J Med Virol. 2017 Oct 27. doi: 10.1002/jmv.24986.
    PubMed     Text format     Abstract available


  75. MEZGEBO TA, Niguse S, Kahsay AG, Hailekiros H, et al
    HEPATITIS B VIRUS INFECTION AND ASSOCIATED RISK FACTORS AMONG PREGNANT WOMEN ATTENDING ANTENATAL CARE IN HEALTH FACILITIES OF TIGRAY, NORTHERN ETHIOPIA.
    J Med Virol. 2017 Oct 27. doi: 10.1002/jmv.24987.
    PubMed     Text format     Abstract available


  76. GEWAID H, Mesalam AA, Ibrahim AA, Abdel Shafy DN, et al
    Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate.
    J Med Virol. 2017 Oct 24. doi: 10.1002/jmv.24977.
    PubMed     Text format     Abstract available


  77. SILVA RAD, de Souza Todao J, Kamitani FL, Benedito Silva AE, et al
    MOLECULAR CHARACTERIZATION OF HEPATITIS C VIRUS IN END-STAGE RENAL DISEASE PATIENTS UNDER HEMODIALYSIS.
    J Med Virol. 2017 Oct 24. doi: 10.1002/jmv.24976.
    PubMed     Text format     Abstract available


  78. JAVAN B, Reza Kalani M, Shahbazi M
    Interleukin-1 Gene Cluster Haplotype Analysis in the Chronic Outcome Prediction of the Hepatitis B Virus Infection.
    J Med Virol. 2017 Oct 11. doi: 10.1002/jmv.24972.
    PubMed     Text format     Abstract available


  79. AL-RADDADI RM, Dashash NA, Alghamdi HA, Al-Raddadi ZM, et al
    Hepatitis C virus infection in Jeddah City, Saudi Arabia: Seroprevalence and knowledge.
    J Med Virol. 2017 Oct 11. doi: 10.1002/jmv.24973.
    PubMed     Text format     Abstract available


  80. CARRASCO I, Arias A, Benitez-Gutierrez L, Lledo G, et al
    Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.
    J Med Virol. 2017 Oct 9. doi: 10.1002/jmv.24971.
    PubMed     Text format     Abstract available


  81. AMPONSAH-DACOSTA E, Selabe SG, Mphahlele MJ
    Evolution of the serologic and virologic course of occult HBV infection in therapy experienced HIV co-infected patients.
    J Med Virol. 2017 Oct 2. doi: 10.1002/jmv.24956.
    PubMed     Text format     Abstract available


    September 2017
  82. RAHMAN M, Hossain ME, Afrad MH, Hasan R, et al
    Hepatitis C Virus infections among clients attending an HIV testing and counseling center in Dhaka, Bangladesh.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24955.
    PubMed     Text format     Abstract available


  83. CIANCIO A, Bosio R, Bo S, Pellegrini M, et al
    SIGNIFICANT IMPROVEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS WITH HCV INFECTION RESPONDING TO DIRECT-ACTING ANTIVIRAL AGENTS.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24954.
    PubMed     Text format     Abstract available


  84. ALVARADO-ESQUIVEL C, Sanchez-Anguiano LF, Hernandez-Tinoco J, Alvarado-Felix AO, et al
    Seroepidemiology of hepatitis E virus infection in pigs in Durango State, Mexico.
    J Med Virol. 2017 Sep 15. doi: 10.1002/jmv.24951.
    PubMed     Text format     Abstract available


  85. OGASAWARA N, Kobayashi M, Akuta N, Kominami Y, et al
    Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    J Med Virol. 2017 Sep 14. doi: 10.1002/jmv.24950.
    PubMed     Text format     Abstract available


  86. AHMED AM, Doheim MF, Mattar OM, Sherif NA, et al
    Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
    J Med Virol. 2017 Sep 11. doi: 10.1002/jmv.24947.
    PubMed     Text format     Abstract available


  87. SCHULZ TR, Edwards R, Thurnheer MC, Yuen L, et al
    Hepatitis B amongst Immigrants from Myanmar: Genotypes and their Clinical Relevance.
    J Med Virol. 2017 Sep 8. doi: 10.1002/jmv.24939.
    PubMed     Text format     Abstract available


  88. CAVARETTO LDSP, Motta-Castro ARC, Teles SA, de Souza FQ, et al
    Epidemiological and molecular analysis of hepatitis B virus infection in manicurists in Central Brazil.
    J Med Virol. 2017 Sep 8. doi: 10.1002/jmv.24940.
    PubMed     Text format     Abstract available


  89. ZHANG K, Liu Y, Chen R, Li Q, et al
    Antigenicity reduction contributes mostly to poor detectability of HBsAg by hepatitis B virus (HBV) S-gene mutants isolated from individuals with occult HBV infection.
    J Med Virol. 2017 Sep 6. doi: 10.1002/jmv.24936.
    PubMed     Text format     Abstract available


    August 2017
  90. MA X, Sun D, Li C, Ying J, et al
    Chronic hepatitis B virus infection and preterm labor(birth) in pregnant women-An updated systematic review and meta-analysis.
    J Med Virol. 2017 Aug 29. doi: 10.1002/jmv.24927.
    PubMed     Text format     Abstract available


  91. DEHGHANI-DEHEJ F, Sarvari J, Esghaei M, Hosseini SY, et al
    Presence of Different Hepatitis C Virus Genotypes in Plasma and Peripheral Blood Mononuclear Cell Samples of Iranian Patients with HIV Infection.
    J Med Virol. 2017 Aug 28. doi: 10.1002/jmv.24925.
    PubMed     Text format     Abstract available


  92. SHEPHERD SJ, McDonald SA, Palmateer NE, Gunson RN, et al
    HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24919.
    PubMed     Text format     Abstract available


  93. SCHNELL G, Tripathi R, Krishnan P, Beyer J, et al
    Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24923.
    PubMed     Text format     Abstract available


  94. MAHMUD S, Kanaani ZA, Chemaitelly H, Chaabna K, et al
    Hepatitis C Virus Genotypes in the Middle East and North Africa: Distribution, Diversity, and Patterns.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24921.
    PubMed     Text format     Abstract available


  95. ZHAO C, Geng Y, Huang W, Ma H, et al
    Valuable Antibody Detection Method for Classifying Hepatitis E Virus Genotypes.
    J Med Virol. 2017 Aug 17. doi: 10.1002/jmv.24915.
    PubMed     Text format     Abstract available


  96. YANG T, Chen Q, Li D, Wang T, et al
    High prevalence of syphilis, HBV and HCV co-infection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital.
    J Med Virol. 2017 Aug 9. doi: 10.1002/jmv.24912.
    PubMed     Text format     Abstract available


  97. JOSE-ABREGO A, Panduro A, Fierro NA, Roman S, et al
    High prevalence of HBV infection, detection of subgenotypes F1b, A2 and D4 and differential risk factors among Mexican risk populations with low socioeconomic status.
    J Med Virol. 2017 Aug 9. doi: 10.1002/jmv.24913.
    PubMed     Text format     Abstract available


  98. TSATSRALT-OD B, Primadharsini PP, Nishizawa T, Ohnishi H, et al
    Distinct changing profiles of hepatitis A and E virus infection among patients with acute hepatitis in Mongolia: The first report of the full genome sequence of a novel genotype 1 hepatitis E virus strain.
    J Med Virol. 2017 Aug 4. doi: 10.1002/jmv.24907.
    PubMed     Text format     Abstract available


    July 2017
  99. WEHMEYER MH, Ingiliz P, Christensen S, Hueppe D, et al
    Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03).
    J Med Virol. 2017 Jul 15. doi: 10.1002/jmv.24903.
    PubMed     Text format     Abstract available


  100. LISBOA NETO G, M Malta F, Gomes-Gouvea MS, F Noble C, et al
    CHARACTERIZATION OF CLINICAL PREDICTORS OF NATURALLY OCCURRING NS3/NS4A PROTEASE POLYMORPHISM IN GENOTYPE 1 HEPATITIS C VIRUS MONO AND HIV CO-INFECTED PATIENTS.
    J Med Virol. 2017 Jul 12. doi: 10.1002/jmv.24900.
    PubMed     Text format     Abstract available


  101. LU J, Xiang X, Cao Z, Wang W, et al
    Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China.
    J Med Virol. 2017 Jul 3. doi: 10.1002/jmv.24894.
    PubMed     Text format     Abstract available


  102. OSAWA M, Akuta N, Suzuki F, Fujiyama S, et al
    Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus.
    J Med Virol. 2017 Jul 1. doi: 10.1002/jmv.24890.
    PubMed     Text format     Abstract available


    June 2017
  103. CHEN T, Xun Z, Lin J, Fu Y, et al
    Association between mitochondrial DNA content and baseline serum levels of HBsAg in chronic hepatitis B infection.
    J Med Virol. 2017 Jun 28. doi: 10.1002/jmv.24886.
    PubMed     Text format     Abstract available


  104. KAN H, Imamura M, Kawakami Y, Daijo K, et al
    Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
    J Med Virol. 2017 Jun 28. doi: 10.1002/jmv.24885.
    PubMed     Text format     Abstract available


  105. COSTANTINO A, Coppola N, Spada E, Bruni R, et al
    Hepatitis A virus strains circulating during 1997-2015 in Campania, a Southern Italy region with periodic outbreaks.
    J Med Virol. 2017 Jun 16. doi: 10.1002/jmv.24880.
    PubMed     Text format     Abstract available


  106. ADEYEMI OO, Herod MR, Oladiji F, Fakunle YM, et al
    A multi-template multiplex PCR assay for hepatitis B virus and human beta-globin.
    J Med Virol. 2017 Jun 15. doi: 10.1002/jmv.24877.
    PubMed     Text format     Abstract available


  107. AHN HS, Park BJ, Han SH, Kim YH, et al
    Prevalence and Genetic Features of Rabbit Hepatitis E Virus in Korea.
    J Med Virol. 2017 Jun 15. doi: 10.1002/jmv.24875.
    PubMed     Text format     Abstract available


  108. CAI Y, Qin SY, Qian A, Xu P, et al
    Seroprevalence and risk factors of hepatitis E virus infection among the Korean, Manchu, Mongol and Han ethnic groups in eastern and northeastern China.
    J Med Virol. 2017 Jun 3. doi: 10.1002/jmv.24871.
    PubMed     Text format     Abstract available


  109. SAGNELLI C, Ciccozzi M, Coppola N, Minichini C, et al
    Molecular diversity in irregular or refugee immigrant patients with HBV-genotype-E infection living in the metropolitan area of Naples.
    J Med Virol. 2017;89:1015-1024.
    PubMed     Text format     Abstract available


  110. MOBARAK L, Omran D, Nabeel MM, Zakaria Z, et al
    Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease.
    J Med Virol. 2017;89:1062-1068.
    PubMed     Text format     Abstract available


    May 2017
  111. SHI X, Jiao B, Chen Y, Li S, et al
    MxA Is A Positive Regulator of Type I IFN Signaling in HCV Infection.
    J Med Virol. 2017 May 31. doi: 10.1002/jmv.24867.
    PubMed     Text format     Abstract available


  112. HUANG X, Ma C, Zhang Q, Shi Q, et al
    Impact of "a" Determinant Mutations on Detection of Hepatitis B Surface Antigen (HBsAg) in HBV Strains from Chinese Patients with Occult Hepatitis B.
    J Med Virol. 2017 May 17. doi: 10.1002/jmv.24859.
    PubMed     Text format     Abstract available


  113. DOS SANTOS MIMA, Rugiere SP, Stocker A, Schinoni MI, et al
    Mutations Associated With Drug Resistance and Prevalence of Vaccine Escape Mutations In Patients With Chronic Hepatitis B Infection.
    J Med Virol. 2017 May 13. doi: 10.1002/jmv.24853.
    PubMed     Text format     Abstract available


  114. KAR P, Kumar D, Gumma PK, Chowdhury SJ, et al
    Down regulation of TRIF, TLR3 and MAVS in HCV infected liver correlates with the outcome of infection.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24849.
    PubMed     Text format     Abstract available


  115. HUDSON B, Walker AJ, Irving WL
    Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24848.
    PubMed     Text format     Abstract available


  116. RAZIKY ME, Zayed NA, Baki AA, Mansour SA, et al
    ITPA Gene polymorphism (94C>A) Effects on Ribavirin-Induced Anemia during Therapy in Egyptian Patients with Chronic Hepatitis C.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24844.
    PubMed     Text format     Abstract available


  117. SCOGNAMIGLIO P, Piselli P, Fusco M, Pisanti FA, et al
    DECLINING UNAWARENESS OF HCV-INFECTION PARALLEL TO DECLINING PREVALENCE IN SOUTHERN ITALY.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24840.
    PubMed     Text format     Abstract available


  118. TRIPODI G, Larsson SB, Norkrans G, Lindh M, et al
    Smaller reduction of hepatitis B virus DNA in liver tissue than in serum in patients losing HBeAg.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24841.
    PubMed     Text format     Abstract available


  119. LONG F, Yu W, Yang C, Wang J, et al
    High prevalence of Hepatitis E virus infection in goats.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24843.
    PubMed     Text format     Abstract available


    April 2017
  120. SHINDANO TA, Horsmans Y, Kabamba BM
    GENETIC AND PHYLOGENIC CHARACTERISATION OF HEPATITIS B VIRUS IN THE EASTERN PART OF THE DEMOCRATIC REPUBLIC OF CONGO.
    J Med Virol. 2017 Apr 29. doi: 10.1002/jmv.24837.
    PubMed     Text format     Abstract available


  121. CHAN MC, Cheng FW, Sze KH, Wong AH, et al
    Hepatitis B infection acquired after haematopioetic stem cell transplant through horizontal mode.
    J Med Virol. 2017 Apr 29. doi: 10.1002/jmv.24835.
    PubMed     Text format     Abstract available


  122. DE PASCHALE M, Manco MT, Arpino O, Ricucci V, et al
    Threshold value of LIAISON XL anti-HCV screening assay predicting positive immunoblotting results.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24831.
    PubMed     Text format     Abstract available


  123. WANG J, Zhang H, Zhang Y, Jiang D, et al
    Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24830.
    PubMed     Text format     Abstract available


  124. JIAO X, Fan Z, Chen H, He P, et al
    Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24829.
    PubMed     Text format     Abstract available


  125. EL-MOWAFY M, Elgaml A, El-Mesery M, Elegezy M, et al
    Molecular analysis of Hepatitis B virus sub-genotypes and incidence of preS1/preS2 region mutations in HBV-infected Egyptian patients from Mansoura.
    J Med Virol. 2017 Apr 8. doi: 10.1002/jmv.24828.
    PubMed     Text format     Abstract available


    March 2017
  126. MENDIZABAL M, Haddad L, Gallardo PE, Ferrada A, et al
    Ombitasvir/paritaprevir/ritonavir/dasabuvir +/- ribavirin is safe and effective in HCV infected patients in a real-life cohort from Latin America.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24816.
    PubMed     Text format     Abstract available


  127. KHALIFA RH, Labib DA, Kamel MA, Shahin RM, et al
    Role of ApoB-516C/T promoter gene polymorphism in the risk of Hepatitis C virus infection in Egyptian patients and in gender susceptibility.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24815.
    PubMed     Text format     Abstract available


  128. HIRAMATSU K, Matsuda H, Nemoto T, Nosaka T, et al
    Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C.
    J Med Virol. 2017 Mar 22. doi: 10.1002/jmv.24814.
    PubMed     Text format     Abstract available


  129. EIJSVOOGEL NB, Hollegien MI, Bok LA, Derksen-Lubsen A, et al
    Declining antibody levels after hepatitis B vaccination in Down syndrome: a need for booster vaccination?
    J Med Virol. 2017 Mar 21. doi: 10.1002/jmv.24813.
    PubMed     Text format     Abstract available


  130. CICCOZZI M, Chaouch H, Lo Presti A, Taffon S, et al
    Evolutionary dynamics of HBV-D7 subgenotype in Tunisia.
    J Med Virol. 2017;89:469-475.
    PubMed     Text format     Abstract available


  131. ZHANG Y, Wang L, Zeng H, Gong W, et al
    Development and validation of a new serum standard for the measurement of anti-HEV antibodies in animals.
    J Med Virol. 2017;89:497-501.
    PubMed     Text format     Abstract available


    September 2016
  132. JOGEDA EL, Huik K, Pauskar M, Kallas E, et al
    The prevalence and genotypes of GBV-C and its associations with HIV infection among persons who inject drugs in Eastern Europe.
    J Med Virol. 2016 Sep 7. doi: 10.1002/jmv.24683.
    PubMed     Text format     Abstract available


    June 2016
  133. KIM MN, Park JY, Ahn SH, Kim BK, et al
    Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy.
    J Med Virol. 2016 Jun 30. doi: 10.1002/jmv.24616.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: